Eli Lilly and Company (NYSE:LLY) has been given a $73.00 price objective by investment analysts at BMO Capital Markets in a research note issued on Wednesday, November 1st. The brokerage currently has a “sell” rating on the stock. BMO Capital Markets’ price target indicates a potential downside of 12.24% from the stock’s current price.
Several other research analysts also recently commented on LLY. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Leerink Swann downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $93.00 to $90.00 in a research note on Wednesday, July 26th. Cowen and Company reissued a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a research note on Wednesday, July 26th. Finally, Berenberg Bank reissued a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research note on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $89.76.
Eli Lilly and (LLY) opened at $83.18 on Wednesday. The company has a market capitalization of $91,590.00, a PE ratio of 20.27, a P/E/G ratio of 1.83 and a beta of 0.34. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.88 earnings per share. equities analysts expect that Eli Lilly and will post 4.21 EPS for the current year.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $82.53, for a total value of $15,680,700.00. Following the transaction, the insider now owns 123,682,287 shares in the company, valued at $10,207,499,146.11. The disclosure for this sale can be found here. Insiders have sold a total of 772,003 shares of company stock worth $64,837,441 over the last 90 days. Company insiders own 0.20% of the company’s stock.
Several institutional investors have recently bought and sold shares of LLY. BlackRock Inc. boosted its holdings in shares of Eli Lilly and by 2,628.5% during the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Eli Lilly and by 7,093.5% during the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after buying an additional 9,223,251 shares in the last quarter. Dodge & Cox boosted its holdings in shares of Eli Lilly and by 22,094.9% during the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after buying an additional 5,964,955 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Eli Lilly and by 91.1% during the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after purchasing an additional 2,714,505 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Eli Lilly and by 3.3% during the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after purchasing an additional 2,181,701 shares during the period. Hedge funds and other institutional investors own 76.61% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with our FREE daily email newsletter.